Onconova Therapeutics Analyst Ratings
Onconova Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 1258.19% | HC Wainwright & Co. | $11 → $11 | Reiterates | Buy → Buy |
| 08/11/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 06/14/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 06/06/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/25/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 05/16/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 04/21/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Upgrades | Neutral → Buy |
| 03/01/2022 | 764.3% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 05/18/2021 | 393.89% | Guggenheim | → $4 | Initiates Coverage On | → Buy |
| 12/22/2020 | — | Noble Capital Markets | Upgrades | Market Perform → Outperform | |
| 08/24/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 07/25/2019 | 1381.66% | Noble Capital Markets | → $12 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月12日 | 1258.19% | HC Wainwright公司 | $11→$11 | 重申 | 购买→购买 |
| 2023年08月11日 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | 购买→购买 |
| 2023/06/14 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | →购买 |
| 06/06/2023 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | 购买→购买 |
| 2023年05月25日 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | →购买 |
| 2023年05月16日 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | 购买→购买 |
| 04/21/2023 | 1258.19% | HC Wainwright公司 | →$11 | 升级 | 中性→购买 |
| 03/01/2022 | 764.3% | 拉登堡·塔尔曼 | →$7 | 开始承保 | →购买 |
| 2021/05/18 | 393.89% | 古根海姆 | →$4 | 开始承保 | →购买 |
| 12/22/2020 | - | 来宝资本市场 | 升级 | 市场表现优于→ | |
| 08/24/2020 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 2019年07月25日 | 1381.66% | 来宝资本市场 | →$12 | 开始承保 | →跑赢大盘 |
What is the target price for Onconova Therapeutics (ONTX)?
Onconova治疗公司(ONTX)的目标价格是多少？
The latest price target for Onconova Therapeutics (NASDAQ: ONTX) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $11.00 expecting ONTX to rise to within 12 months (a possible 1258.19% upside). 7 analyst firms have reported ratings in the last year.
昂科诺娃治疗公司(纳斯达克代码：ONTX)的最新目标价是由HC Wainwright&Co.于2023年10月12日报道的。这家分析公司将目标价定为11美元，预计ONTX将在12个月内上涨至(可能上涨1258.19%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Onconova Therapeutics (ONTX)?
Onconova治疗公司(ONTX)的最新分析师评级是多少？
The latest analyst rating for Onconova Therapeutics (NASDAQ: ONTX) was provided by HC Wainwright & Co., and Onconova Therapeutics reiterated their buy rating.
昂科诺娃治疗公司(纳斯达克代码：ONTX)的最新分析师评级由HC Wainwright&Co.提供，Onconova治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Onconova Therapeutics (ONTX)?
Onconova治疗公司(ONTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Onconova Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Onconova Therapeutics was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Onconova治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Onconova治疗公司的上一次评级是在2023年10月12日提交的，所以你应该预计下一次评级将在2024年10月12日左右的某个时候提供。
Is the Analyst Rating Onconova Therapeutics (ONTX) correct?
分析师对Onconova Treeutics(ONTX)的评级正确吗？
While ratings are subjective and will change, the latest Onconova Therapeutics (ONTX) rating was a reiterated with a price target of $11.00 to $11.00. The current price Onconova Therapeutics (ONTX) is trading at is $0.81, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Onconova治疗公司(ONTX)评级被重申，目标价在11.00美元至11.00美元之间。Onconova治疗公司(ONTX)目前的交易价格为0.81美元，超出了分析师的预测范围。